Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Patients With Non-Hodgkin’s Lymphoma and Anemia
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 5/26/2005
Phase: II
An open label, randomized, multi-center, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of Mircera at different dosing intervals in patients with chronic renal anemia who are not on renal replacement therapy.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 2/1/2006
Phase: II
An open-label, multi-center, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of Mircera at different dosing intervals in dialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: II
An open-label, multicenter, randomized study to determine dose conversion factors at different frequencies of administration after switching from maintenance treatment with subcutaneous epoetin alfa or beta to maintenance treatment with subcutaneous Mircera in dialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: II
An open-label, multi-center, randomized study to determine dose conversion factors at different frequencies of administration after switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Mircera in hemodialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered with pre-filled syringes for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered subcutaneously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using subcutaneous injections of Mircera in patients with chronic kidney disease who are not on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using intravenous injections of Mircera in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
Product Name: Mircera [methoxy polythylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Multiple Myeloma.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Product Name: Mircera [mehtoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epeotin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients WIth Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcuteneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Patients With Chronic Renal Anemia Who Are on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
CARISMA Study: A Study of Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
MISTRAL Study: A Study of Monthly Subcutaneous Mircera for Maintenance Treatment of Patients WIth Chronic Kidney Disease on Peritoneal Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of the Safety, Tolerability and Efficacy With Respect to the Maintenance of Hemoglobin Levels of Once Monthly Mircera in Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of the Safety, Tolerability and Efficacy With Respect to Raising Hemoglobin Levels of Two-Weekly Mircera in Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 3/31/2005
Phase: IV
MARCH study: Management of Anemia Under Radiochemotherapy : an Open, Randomized, Multi-Center Study of the Effect of NeoRecormon on Treatment Outcome in Patients With Advanced Cervical Cancer Stage IIB-IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin).
Product Name: NeoRecormon [epoetin beta]
Date of Report: 5/2/2005
Phase: III
Open, randomized, parallel group, multi-center study to investigate the effect of early anemia correction with epoetin beta on the reduction of cardiovascular risk in patients with chronic renal anemia who are not on renal replacement therapy (CREATE).
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
Immediate pain at the injection site of subcutaneous administered erythropoiesis stimulating agents (ESA’s): comparison of NeoRecormon (NR) and AraNesp (A)
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: III
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Solid Tumors
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: II
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Breast Cancer Undergoing Chemotherapy
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Anemia in Patients Receiving Chemotherapy
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study to Evaluate NeoRecormon (Epoetin Beta) in Anemic Patients with Solid Tumors Receiving Chemotherapy
Product Name: NeoRecormon [epoetin beta]
Date of Report: 10/28/2005
Phase: II
An open-label, multi-center study to investigate safety of once weekly NeoRecormon therapy in patients with refractory anemia.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Patients With Lymphoid Malignancies
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Different Methods of Administration of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies
Product Name: NeoRecormon [epoetin beta]
Date of Report: 3/1/2006
Phase: III
An open, randomized, multi-center trial to investigate the effect of anemia correction on cardiac structure and function in patients with early diabetic nephropathy (ACORD).
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
Study of NeoRecormon (Epoetin Beta) in Anemic Patients with Solid Tumors
Product Name: NeoRecormon [epoetin beta]
Date of Report: 5/1/2006
Phase: III
Open label, randomized, multicenter, two-arm study to investigate the impact of NeoRecormon® (epoetin beta) treatment on survival, quality of life, outcome of antineoplastic therapy, and anemia in patients with metastatic breast cancer.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 7/1/2006
Phase: IV
Open label, multicenter study to investigate the safety of once weekly NeoRecormon therapy in anemic patients with low-grade non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or multiple myeloma.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Hematologic Malignancies.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 8/1/2006
Phase: IV
Open label, multicenter study to investigate the safety of once weekly NeoRecormon therapy in anemic patients with non-myeloid malignancy.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 12/1/2006
Phase: III
Multicenter Open Label Study of NeoRecormon Prevention and Treatment for Anemia in Adult Patients with Solid Tumors and Treated with Platinum-Based Chemotherapy Prone to Induce Anemia.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon in Patients With Chronic Kidney Disease.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 12/18/2006
Phase: III
Multicenter, open label study of NeoRecormon treatment for anemia in adult patients with Multiple Myeloma, Low Grade Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia who have a relatively Erythropoietin Deficiency and are Receiving anti-tumor Chemotherapy.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
NADIR Study: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Renal Failure Who Are Not on Dialysis.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: III
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 3/1/2007
Phase: IV
Comparative, monocenter, randomized, single-blind, cross-over study in healthy volunteers comparing local pain after subcutaneous injection of epoetin beta (NeoRecormon®) versus darbepoetin alfa (Aranesp®).
Product Name: NeoRecormon [epoetin beta]
Date of Report: 3/1/2007
Phase: II
An open-label study to investigate the efficacy and safety of epoetin beta 30 000 IU once weekly in anemic patients with metastatic breast cancer.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 7/2/2007
Phase: IV
An open-label study of the safety of NeoRecormon in patients with solid tumors being treated with platinum capable of inducing anemia.
Product Name: NeoRecormon [epoetin beta]
Date of Report: 8/1/2007
Phase: III
An open-label, randomized, multicenter trial investigating the efficacy and safety of once weekly (reduced administration frequency) NeoRecormon therapy versus thrice weekly NeoRecormon therapy in anemic patients with metastatic solid tumors (breast, lung, colorectal, ovarian, cervical and prostate cancer) receiving chemotherapy (or scheduled to receive chemotherapy) for at least 9 weeks.
Product Name: NeoRecormon [epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients WIth Chronic Hepatitis C.
